La pathologie et la neuroinflammation liées à TDP-43 dans des différents modéles d'ischémie cérébrale : le rôle thérapeutique potential d'un analogue de la Withaferin A (IMS-088)

Authors: Thammisetty, Saisampath
Advisor: Calon, FrédéricKriz, Jasna
Other Title(s): La pathologie et la neuroinflammation liées à TDP-43 dans des différents modèles d'ischémie cérébrale: le rôle thérapeutique potential d'un analogue de la Withaferin A (IMS-088)
Abstract: Stroke results from insufficient blood supply to the brain and is the third leading cause of death in the world. Experimentally and clinically, stroke is followed by acute and prolonged inflammatory responses, and about a third of stroke survivors suffer from post-stroke dementia. Although numerous mechanisms have been explained to be involved in stroke pathology, an effective therapy to minimize post stroke consequences is still to be established. In this thesis, we have explored TDP-43 protein pathology and associated neuroinflammation in middle cerebral artery occlusion model (MCAO) in aging (chapter 2) and in chronic cerebral hypo-perfusion model(CCH): model for vascular dementia and therapeutic effects of IMS-088 in the chronic cerebral hypo-perfusion (CCH) model (chapter 3). In the chapter 2, we observed age-dependant cytoplasmic accumulation of ubiquitinated TDP-43 can modulate the post-ischemic inflammatory responses like microglial activation and large infarctionsafter acute stroke. We also observedthat an increase / over expression of TDP-43, potentiates NF-κB response and ischemic injury after stroke. Finally, we observed the presence of cytoplasmic TDP-43 immunoreactive structures in post-mortem-stroke human brain tissues.In the chapter 3, we reported that CCH induces cytoplasmic accumulation and formation of insoluble phospho-TDP-43 aggregates in cortical neurons. Presence of cytoplasmic TDP-43 was also detected in human disease (vasculardementia). Further, mislocalizationof TDP-43 was associated with microglial and NF-κB activation as well as development of cognitive and motor impairments after 2 months of CCH. Finally, in chapter 3 we studied the efficacy of a novel drug IMS-088 (semi-synthetic analog of withaferin A) which is aimed to modulate post ischemic inflammation by targeting NF-κB pathway in the CCH mice. After 2 months of oral IMS-088 treatment, CCH mice showed marked improvement in cognitive and motor outcome along with restoration of nuclear vs cytoplasmic TDP-43 balance and decreased microglial activation, cell death and improved autophagy. Basing on these evidences, IMS-088 should be considered as potential candidate for therapeutic interventions in CCH and other TDP-43 proteinopathies.
Document Type: Thèse de doctorat
Issue Date: 2018
Open Access Date: 29 November 2019
Permalink: http://hdl.handle.net/20.500.11794/37363
Grantor: Université Laval
Collection:Thèses et mémoires

Files in this item:
Description SizeFormat 
34800.pdf2.86 MBAdobe PDFThumbnail
View/Open
All documents in CorpusUL are protected by Copyright Act of Canada.